DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.68 (2022) >

Please use this identifier to cite or link to this item: http://ir.fmu.ac.jp/dspace/handle/123456789/1642

Files in This Item:

File Description SizeFormat
FksmJMedSci_68_p1.pdf246.17 kBAdobe PDFDownload
Title: Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer
Authors: Sugimoto, Mitsuru
Takagi, Tadayuki
Suzuki, Rei
Konno, Naoki
Asama, Hiroyuki
Sato, Yuki
Irie, Hiroki
Okubo, Yoshinori
Nakamura, Jun
Takasumi, Mika
Hashimoto, Minami
Kato, Tsunetaka
Kobashi, Ryoichiro
Hikichi, Takuto
Ohira, Hiromasa
Affiliation: 消化器内科学講座
Source title: Fukushima Journal of Medical Science
Volume: 68
Issue: 1
Start page: 1
End page: 10
Issue Date: 2022
Abstract: Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. However, as oxaliplatin and paclitaxel are common neurotoxic drugs, chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse effect of both treatments. As there are no agents recommended in the ASCO guidelines, we review the methods used to treat CIPN caused by PC treatment. The efficacy of duloxetine was observed in a large randomized controlled trial (RCT). In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs. Although duloxetine and pregabalin can be effective for CIPN, they have several side effects. Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future.
Publisher: The Fukushima Society of Medical Science
Publisher (Alternative foam): 福島医学会
language: eng
URI: http://ir.fmu.ac.jp/dspace/handle/123456789/1642
Full text URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/1642/1/FksmJMedSci_68_p1.pdf
ISSN: 0016-2590
DOI: 10.5387/fms.2021-32
PubMed ID: 35197393
Related Page: https://doi.org/10.5387/fms.2021-32
Rights: © 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
Rights: https://creativecommons.org/licenses/by-nc-sa/4.0/
Appears in Collections:Vol.68 (2022)

Files in This Item:

File Description SizeFormat
FksmJMedSci_68_p1.pdf246.17 kBAdobe PDFDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard